Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology
Disease Category: Inflammatory Bowel Disease
Trial Information
Stool DNA Markers for the Detection of Dysplasia and Carcinoma in Inflammatory Bowel Disease Patients.
The purpose of this study is to see whether an experimental
stool DNA study (a test that has not yet been proven to be a valid
test for cancer) may be able to accurately identify Inflammatory
Bowel Disease patients with or at high risk of developing dysplasia
(pre-cancer) or colorectal cancer. The test will analyze the DNA
that is shed from intestinal cells into the stool and compare them
with results from regular exams or surgical procedures you may have
scheduled. Upon entering the study, a blood sample will be taken
and you will be given two stool kits to take home for sample
collection. Some follow up samples will be necessary.
Compensation Provided
Patient Inclusion/Exclusion Criteria:
You are eligible for this study if you have an IBD diagnosis
(either Crohn's Disease or Ulcerative Colitis) for at least 8
years and are either undergoing active surveillance or are
scheduled for colectomy.
You are not eligible for this study if you have had an IBD
diagnosis (either Crohn's disease of Ulcerative Colitis) for
less than 8 years or if you have already had a colectomy.
Patricia Thenor, Research Coordinator
Mount Sinai Medical Center
One Gustave L. Levy Place
New York, NY 10029
Phone: 212-659-8212
Fax: 212-849-2564
EMail: patricia.thenor@mssm.edu
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
